Pub Date : 2024-03-01Epub Date: 2024-01-25DOI: 10.1161/SVIN.123.001118
Sergio A Pineda-Castillo, Evan R Jones, Keely A Laurence, Lauren R Thoendel, Tanner L Cabaniss, Yan D Zhao, Bradley N Bohnstedt, Chung-Hao Lee
Background: Currently, endovascular treatment of intracranial aneurysms (ICAs) is limited by low complete occlusion rates. The advent of novel endovascular technology has expanded the applicability of endovascular therapy; however, the superiority of novel embolic devices over the traditional Guglielmi detachable coils (GDCs) is still debated. We performed a systematic review of literature that reported Raymond-Roy occlusion classification (RROC) rates of modern endovascular devices to determine their immediate and follow-up occlusion effectiveness for the treatment of unruptured saccular ICAs.
Methods: A search was conducted using electronic databases (PUBMED, Cochrane, ClinicalTrials.gov, Web of Science). We retrieved studies published between 2000-2022 reporting immediate and follow-up RROC rates of subjects treated with different endovascular ICA therapies. We extracted demographic information of the treated patients and their reported angiographic RROC rates.
Results: A total of 80 studies from 15 countries were included for data extraction. RROC rates determined from angiogram were obtained for 21,331 patients (72.5% females, pooled mean age: 58.2 (95% CI: 56.8-59.6), harboring 22,791 aneurysms. The most frequent aneurysm locations were the internal carotid artery (46.4%, 95% CI: 41.9%-50.9%), the anterior communicating artery (26.4%, 95% CI: 22.5%-30.8%), the middle cerebral artery (24.5%, 95% CI:19.2%-30.8%) and the basilar tip (14.4%, 95% CI:11.3%-18.3%). The complete occlusion probability (RROC-I) was analyzed for GDCs, the Woven EndoBridge (WEB), and flow diverters. The RROC-I rate was the highest in balloon-assisted coiling (73.9%, 95% CI: 65.0%-81.2%) and the lowest in the WEB (27.8%, 95% CI:13.2%-49.2%). The follow-up RROC-I probability was homogenous in all analyzed devices.
Conclusions: We observed that the coil-based endovascular therapy provides acceptable rates of complete occlusion, and these rates are improved in balloon-assisted coils. Out of the analyzed devices, the WEB exhibited the shortest time to achieve >90% probability of follow-up complete occlusion (~18 months). Overall, the GDCs remain the gold standard for endovascular treatment of unruptured saccular aneurysms.
{"title":"Systematic Review and Meta-Analysis of Endovascular Therapy Effectiveness for Unruptured Saccular Intracranial Aneurysms.","authors":"Sergio A Pineda-Castillo, Evan R Jones, Keely A Laurence, Lauren R Thoendel, Tanner L Cabaniss, Yan D Zhao, Bradley N Bohnstedt, Chung-Hao Lee","doi":"10.1161/SVIN.123.001118","DOIUrl":"10.1161/SVIN.123.001118","url":null,"abstract":"<p><strong>Background: </strong>Currently, endovascular treatment of intracranial aneurysms (ICAs) is limited by low complete occlusion rates. The advent of novel endovascular technology has expanded the applicability of endovascular therapy; however, the superiority of novel embolic devices over the traditional Guglielmi detachable coils (GDCs) is still debated. We performed a systematic review of literature that reported Raymond-Roy occlusion classification (RROC) rates of modern endovascular devices to determine their immediate and follow-up occlusion effectiveness for the treatment of unruptured saccular ICAs.</p><p><strong>Methods: </strong>A search was conducted using electronic databases (PUBMED, Cochrane, ClinicalTrials.gov, Web of Science). We retrieved studies published between 2000-2022 reporting immediate and follow-up RROC rates of subjects treated with different endovascular ICA therapies. We extracted demographic information of the treated patients and their reported angiographic RROC rates.</p><p><strong>Results: </strong>A total of 80 studies from 15 countries were included for data extraction. RROC rates determined from angiogram were obtained for 21,331 patients (72.5% females, pooled mean age: 58.2 (95% CI: 56.8-59.6), harboring 22,791 aneurysms. The most frequent aneurysm locations were the internal carotid artery (46.4%, 95% CI: 41.9%-50.9%), the anterior communicating artery (26.4%, 95% CI: 22.5%-30.8%), the middle cerebral artery (24.5%, 95% CI:19.2%-30.8%) and the basilar tip (14.4%, 95% CI:11.3%-18.3%). The complete occlusion probability (RROC-I) was analyzed for GDCs, the Woven EndoBridge (WEB), and flow diverters. The RROC-I rate was the highest in balloon-assisted coiling (73.9%, 95% CI: 65.0%-81.2%) and the lowest in the WEB (27.8%, 95% CI:13.2%-49.2%). The follow-up RROC-I probability was homogenous in all analyzed devices.</p><p><strong>Conclusions: </strong>We observed that the coil-based endovascular therapy provides acceptable rates of complete occlusion, and these rates are improved in balloon-assisted coils. Out of the analyzed devices, the WEB exhibited the shortest time to achieve >90% probability of follow-up complete occlusion (~18 months). Overall, the GDCs remain the <i>gold standard</i> for endovascular treatment of unruptured saccular aneurysms.</p>","PeriodicalId":74875,"journal":{"name":"Stroke (Hoboken, N.J.)","volume":"4 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141285531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
William C Merritt, Nicholas Norris, Sophia Robertson, Mark C Preul, Andrew F Ducruet, Timothy A Becker
Background: Untreated intracranial aneurysms can rupture and result in high rates of morbidity and mortality. Although there are numerous approved endovascular aneurysm treatment devices, most require dual anti-platelet therapy, are minimally biocompatible, or are prone to recanalization. Neurovascular Controlled Uniform Rapid Embolic (NeuroCURE) is an innovative polymer gel material with long-term stability, biocompatibility, and hemocompatibility developed for the treatment of large, wide-neck aneurysms.
Methods: Sidewall aneurysms were surgically created in 10 canines and NeuroCURE was injected through a 0.025 microcatheter under a single balloon inflation period. Aneurysm treatment was angiographically assessed post-embolization and pre-term with Raymond-Roy occlusion classification and a qualitative flow grade scale. Aneurysm neck stability and biocompatibility was histologically assessed to grade platelet/fibrin thrombus, percent endothelialization, and neointimal formation. Aneurysm sac stability was assessed by NeuroCURE sac content, inflammation, and neo-angiogenesis scales.
Results: Explanted aneurysms exhibited a smooth surface at the aneurysm neck with nearly complete neointimal coverage at 3-months. By 6-months, neck endothelialization was 100% in all animals (average Raymond-Roy occlusion classification of 1.2), with no instances of aneurysm recanalization or parent vessel flow compromise. Biocompatibility assessments verified a lack of inflammatory response, neo-angiogenesis, and platelet/fibrin thrombus formation.
Conclusion: The NeuroCURE material promotes progressive occlusion of wide-necked side wall aneurysms over time without the need for dual antiplatelet agents. NeuroCURE also promotes neointimal tissue infill without dependence on thrombus formation and thus resists aneurysm recanalization. NeuroCURE remains a compelling investigational device for the treatment of intracranial aneurysms.
{"title":"Large, Wide-Neck, Side-Wall Aneurysm Treatment in Canines Using NeuroCURE: A Novel Liquid Embolic.","authors":"William C Merritt, Nicholas Norris, Sophia Robertson, Mark C Preul, Andrew F Ducruet, Timothy A Becker","doi":"10.1161/svin.123.000857","DOIUrl":"https://doi.org/10.1161/svin.123.000857","url":null,"abstract":"<p><strong>Background: </strong>Untreated intracranial aneurysms can rupture and result in high rates of morbidity and mortality. Although there are numerous approved endovascular aneurysm treatment devices, most require dual anti-platelet therapy, are minimally biocompatible, or are prone to recanalization. Neurovascular Controlled Uniform Rapid Embolic (NeuroCURE) is an innovative polymer gel material with long-term stability, biocompatibility, and hemocompatibility developed for the treatment of large, wide-neck aneurysms.</p><p><strong>Methods: </strong>Sidewall aneurysms were surgically created in 10 canines and NeuroCURE was injected through a 0.025 microcatheter under a single balloon inflation period. Aneurysm treatment was angiographically assessed post-embolization and pre-term with Raymond-Roy occlusion classification and a qualitative flow grade scale. Aneurysm neck stability and biocompatibility was histologically assessed to grade platelet/fibrin thrombus, percent endothelialization, and neointimal formation. Aneurysm sac stability was assessed by NeuroCURE sac content, inflammation, and neo-angiogenesis scales.</p><p><strong>Results: </strong>Explanted aneurysms exhibited a smooth surface at the aneurysm neck with nearly complete neointimal coverage at 3-months. By 6-months, neck endothelialization was 100% in all animals (average Raymond-Roy occlusion classification of 1.2), with no instances of aneurysm recanalization or parent vessel flow compromise. Biocompatibility assessments verified a lack of inflammatory response, neo-angiogenesis, and platelet/fibrin thrombus formation.</p><p><strong>Conclusion: </strong>The NeuroCURE material promotes progressive occlusion of wide-necked side wall aneurysms over time without the need for dual antiplatelet agents. NeuroCURE also promotes neointimal tissue infill without dependence on thrombus formation and thus resists aneurysm recanalization. NeuroCURE remains a compelling investigational device for the treatment of intracranial aneurysms.</p>","PeriodicalId":74875,"journal":{"name":"Stroke (Hoboken, N.J.)","volume":"3 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/46/69/nihms-1924898.PMC10500583.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10305808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ray McCarthy, F. Clarençon, R. Bourcier, Patrick A. Brouwer, A. Consoli, Karen Doyle, Matthew J. Gounis, W. Hacke, Z. Kulcsár, T. Jovin, Mahmood Mirza, M. Mokin, A. Narata, J. Ospel, A. Rai, Marc Ribó, Nobuyuki Sakai, A. Siddiqui, Teresa Ullberg, Osama O. Zaidat, J. Fiehler, D. Liebeskind
{"title":"Proceedings of the Seventh Annual CLOTS Meeting: CLOTS 7.0, Madrid, Spain","authors":"Ray McCarthy, F. Clarençon, R. Bourcier, Patrick A. Brouwer, A. Consoli, Karen Doyle, Matthew J. Gounis, W. Hacke, Z. Kulcsár, T. Jovin, Mahmood Mirza, M. Mokin, A. Narata, J. Ospel, A. Rai, Marc Ribó, Nobuyuki Sakai, A. Siddiqui, Teresa Ullberg, Osama O. Zaidat, J. Fiehler, D. Liebeskind","doi":"10.1161/svin.123.000936","DOIUrl":"https://doi.org/10.1161/svin.123.000936","url":null,"abstract":"","PeriodicalId":74875,"journal":{"name":"Stroke (Hoboken, N.J.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41598287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The rate of incidentally discovered unruptured intracranial aneurysms has increased with the broad availability of neuroimaging. The determination of the risk of rupture of brain aneurysms is challenging. Several clinical scales for aneurysm rupture prediction have been developed. The most common scales are PHASES, ELAPSS, and UIATS. These scales are not routinely used in clinical practice due to inherent shortcomings. In this review, we analyze the risk factors used in generating these scales and the performance of these scales in clinical studies. We also discuss new potential biomarkers and tools to predict aneurysm rupture.
{"title":"Clinical Scales in Aneurysm Rupture Prediction","authors":"S. Sanchez, Jacob M. Miller, E. Samaniego","doi":"10.1161/svin.123.000625","DOIUrl":"https://doi.org/10.1161/svin.123.000625","url":null,"abstract":"The rate of incidentally discovered unruptured intracranial aneurysms has increased with the broad availability of neuroimaging. The determination of the risk of rupture of brain aneurysms is challenging. Several clinical scales for aneurysm rupture prediction have been developed. The most common scales are PHASES, ELAPSS, and UIATS. These scales are not routinely used in clinical practice due to inherent shortcomings. In this review, we analyze the risk factors used in generating these scales and the performance of these scales in clinical studies. We also discuss new potential biomarkers and tools to predict aneurysm rupture.","PeriodicalId":74875,"journal":{"name":"Stroke (Hoboken, N.J.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49072070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karan Patel, Kamil Taneja, Liqi Shu, Linda Zhang, Yunting Yu, M. Abdalkader, Matthew B. Obusan, S. Yaghi, Thanh N. Nguyen, N. Asdaghi, S. Oak, D. Tonetti, J. Siegler
Prior studies have shown benefit for endovascular therapy (EVT) in patients with large‐vessel occlusion and severe deficits, as captured by the National Institutes of Health Stroke Scale. However the benefit of EVT in patients with National Institutes of Health Stroke Scale score <6 is unclear. We queried the National Inpatient Sample (2018–2020) for patients with a large‐vessel occlusion of the internal carotid or middle cerebral artery with a National Institutes of Health Stroke Scale score <6, and compared outcomes between patients treated with EVT versus best medical management, using propensity score matching. The primary outcome was routine discharge (home or self‐care). Secondary outcomes were in‐hospital mortality, intracerebral hemorrhage, and length of stay. Primary and secondary outcomes were evaluated using multivariable regression adjusted for baseline characteristics, stroke severity, and treatment with thrombolysis. Of the 212 515 patients with an internal carotid artery/middle cerebral artery stroke, 49 115 met the inclusion criteria for our study. A total of 8035 patients were treated with EVT, and 41 080 were treated with best medical management. Patients treated with EVT had increased odds of routine discharge (adjusted odds ratio [OR], 1.78 [95% CI, 1.57–2.01]; P <0.001), shorter length of hospital stays (adjusted β, −0.41 [95% CI, −0.63 to −0.19]; P <0.001), and similar rates of death (adjusted OR, 0.70 [95% CI, 0.39–1.24]; P =0.22), compared with patients treated with best medical management. These relationships persisted in the propensity‐matched cohort. Patients treated with EVT compared with best medical management had greater odds of routine discharge, reduced length of stay, and no differences in intracerebral hemorrhage or early mortality. Our findings suggest potential real‐world benefit for EVT in patients with low National Institutes of Health Stroke Scale scores.
{"title":"Anterior Circulation Thrombectomy in Patients With Low National Institutes of Health Stroke Scale Score: Analysis of the National Inpatient Sample","authors":"Karan Patel, Kamil Taneja, Liqi Shu, Linda Zhang, Yunting Yu, M. Abdalkader, Matthew B. Obusan, S. Yaghi, Thanh N. Nguyen, N. Asdaghi, S. Oak, D. Tonetti, J. Siegler","doi":"10.1161/svin.123.000998","DOIUrl":"https://doi.org/10.1161/svin.123.000998","url":null,"abstract":"\u0000 \u0000 Prior studies have shown benefit for endovascular therapy (EVT) in patients with large‐vessel occlusion and severe deficits, as captured by the National Institutes of Health Stroke Scale. However the benefit of EVT in patients with National Institutes of Health Stroke Scale score <6 is unclear.\u0000 \u0000 \u0000 \u0000 We queried the National Inpatient Sample (2018–2020) for patients with a large‐vessel occlusion of the internal carotid or middle cerebral artery with a National Institutes of Health Stroke Scale score <6, and compared outcomes between patients treated with EVT versus best medical management, using propensity score matching. The primary outcome was routine discharge (home or self‐care). Secondary outcomes were in‐hospital mortality, intracerebral hemorrhage, and length of stay. Primary and secondary outcomes were evaluated using multivariable regression adjusted for baseline characteristics, stroke severity, and treatment with thrombolysis.\u0000 \u0000 \u0000 \u0000 \u0000 Of the 212 515 patients with an internal carotid artery/middle cerebral artery stroke, 49 115 met the inclusion criteria for our study. A total of 8035 patients were treated with EVT, and 41 080 were treated with best medical management. Patients treated with EVT had increased odds of routine discharge (adjusted odds ratio [OR], 1.78 [95% CI, 1.57–2.01];\u0000 P\u0000 <0.001), shorter length of hospital stays (adjusted β, −0.41 [95% CI, −0.63 to −0.19];\u0000 P\u0000 <0.001), and similar rates of death (adjusted OR, 0.70 [95% CI, 0.39–1.24];\u0000 P\u0000 =0.22), compared with patients treated with best medical management. These relationships persisted in the propensity‐matched cohort.\u0000 \u0000 \u0000 \u0000 \u0000 Patients treated with EVT compared with best medical management had greater odds of routine discharge, reduced length of stay, and no differences in intracerebral hemorrhage or early mortality. Our findings suggest potential real‐world benefit for EVT in patients with low National Institutes of Health Stroke Scale scores.\u0000","PeriodicalId":74875,"journal":{"name":"Stroke (Hoboken, N.J.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44687817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Manning, A. Hassan, D. Liebeskind, N. Mueller-Kronast, A. Jadhav, R. Nogueira, D. Yavagal, A. Cheung, J. Wenderoth, O. Zaidat
Time is considered a fundamental driver of treatment success in ischemic stroke reperfusion therapy. First‐pass reperfusion (FPR) is associated with improved outcomes. We explored the association between time to reperfusion, FPR, and functional outcomes in an analysis of the STRATIS (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) registry data. Registry patients with anterior circulation stroke, treated with endovascular thrombectomy and achieving complete or near‐complete expanded Thrombolysis in Cerebral Infarction scale (eTICI) 2c/3 reperfusion per core laboratory assessment were included. FPR was considered eTICI 2c/3 reperfusion in a single device pass. Patients undergoing multipass reperfusion required ≥2 device passes to achieve the same, total, or near‐total reperfusion (eTICI 2c/3). Logistic regression was used to model functional independence, defined as a modified Rankin scale score of 0 to 2 at 3 months, as a function of time to reperfusion, comparing FPR and multipass reperfusion patient populations. Of the 984 patients in the STRATIS registry, 563 patients achieved eTICI 2c/3 reperfusion of anterior circulation large‐vessel occlusions and were eligible for inclusion in the analysis. In patients undergoing multipass reperfusion (n=186), increased time to treatment was associated with a decreased likelihood of a good clinical outcome. Odds ratio for every 60‐minute delay to treatment: 0.71 (95% CI, 0.55–0.90; P =0.005). However, in patients undergoing FPR (n=377), no association between increased time to treatment and good clinical outcomes was observed (odds ratio for every 60‐minute delay to treatment, 0.93 [95% CI, 0.79–1.09]; P =0.347). First‐pass reperfusion may compensate for the effects of delays to reperfusion on functional outcomes in ischemic stroke.
{"title":"Time to Reperfusion Is Not Associated With Functional Outcomes in First‐Pass Reperfusion: Analysis of the STRATIS Registry","authors":"N. Manning, A. Hassan, D. Liebeskind, N. Mueller-Kronast, A. Jadhav, R. Nogueira, D. Yavagal, A. Cheung, J. Wenderoth, O. Zaidat","doi":"10.1161/svin.122.000635","DOIUrl":"https://doi.org/10.1161/svin.122.000635","url":null,"abstract":"\u0000 \u0000 Time is considered a fundamental driver of treatment success in ischemic stroke reperfusion therapy. First‐pass reperfusion (FPR) is associated with improved outcomes. We explored the association between time to reperfusion, FPR, and functional outcomes in an analysis of the STRATIS (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) registry data.\u0000 \u0000 \u0000 \u0000 Registry patients with anterior circulation stroke, treated with endovascular thrombectomy and achieving complete or near‐complete expanded Thrombolysis in Cerebral Infarction scale (eTICI) 2c/3 reperfusion per core laboratory assessment were included. FPR was considered eTICI 2c/3 reperfusion in a single device pass. Patients undergoing multipass reperfusion required ≥2 device passes to achieve the same, total, or near‐total reperfusion (eTICI 2c/3). Logistic regression was used to model functional independence, defined as a modified Rankin scale score of 0 to 2 at 3 months, as a function of time to reperfusion, comparing FPR and multipass reperfusion patient populations.\u0000 \u0000 \u0000 \u0000 \u0000 Of the 984 patients in the STRATIS registry, 563 patients achieved eTICI 2c/3 reperfusion of anterior circulation large‐vessel occlusions and were eligible for inclusion in the analysis. In patients undergoing multipass reperfusion (n=186), increased time to treatment was associated with a decreased likelihood of a good clinical outcome. Odds ratio for every 60‐minute delay to treatment: 0.71 (95% CI, 0.55–0.90;\u0000 P\u0000 =0.005). However, in patients undergoing FPR (n=377), no association between increased time to treatment and good clinical outcomes was observed (odds ratio for every 60‐minute delay to treatment, 0.93 [95% CI, 0.79–1.09];\u0000 P\u0000 =0.347).\u0000 \u0000 \u0000 \u0000 \u0000 First‐pass reperfusion may compensate for the effects of delays to reperfusion on functional outcomes in ischemic stroke.\u0000","PeriodicalId":74875,"journal":{"name":"Stroke (Hoboken, N.J.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45940067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Tonetti, M. Bhattacharyya, M. Koneru, J. English, F. Settecase, Warren T. Kim, P. Patel, Ajith Thomas, T. Jovin, R. Hanel, V. Benalia, G. Cortez, A. Aghaebrahim, E. Sauvageau, M. Abdalkader, Thanh N. Nguyen, P. Klein, A. Dmytriw, Hamza Shaikh
Preliminary in vitro and early clinical experience of the Tenzing 7 delivery catheter demonstrated high success rates of aspiration catheter intracranial delivery with minimal complications. This study aimed to examine the efficacy, safety, and efficiency of the Tenzing 7 delivery catheter to deliver therapeutic devices in aspiration mechanical thrombectomy for acute ischemic strokes using clinical experience from multiple institutions. We performed a retrospective analysis of prospectively collected data from patients with acute ischemic stroke treated with aspiration mechanical thrombectomy using the Tenzing 7 delivery catheter between January 2020 and July 2022 at 6 high volume stroke centers. Primary efficacy outcome was success in aspiration catheter delivery to the face of the thrombus, and primary safety end point was rate of procedural complication. Of a total of 176 patients (mean age 70.1±14.9 years, 56.3% female, 89.2% middle cerebral artery occlusions), first‐pass effect (modified Thrombolysis in Cerebral Infarction score≥2B) was achieved in 90/166 (54.2%) successfully revascularized patients. Tenzing 7 delivered the aspiration catheter of choice to the site of occlusion in 95.9% of cases; the clot was not crossed with Tenzing 7 in 69% of cases. Successful recanalization (modified Thrombolysis in Cerebral Infarction score≥2B) was achieved in 94.9% of cases requiring a median of 1 pass (interquartile range 1–3). Nonflow limiting vessel dissection unrelated to Tenzing 7 occurred in 4 patients (2.3%), and intracranial vessel perforation unrelated to Tenzing 7 occurred in 4 cases (2.3%). This multicenter clinical experience using Tenzing 7 in mechanical thrombectomy demonstrated high rates of technical success and a modest complication rate, similar to the published rates of technical success with other thrombectomy techniques. The Tenzing 7 delivery catheter is effective and safe for the delivery of the aspiration catheter in patients undergoing thrombectomy for acute ischemic stroke.
{"title":"Novel Tenzing 7 Delivery Catheter for Thrombectomy in Acute Stroke: A Clinical Multicenter Experience","authors":"D. Tonetti, M. Bhattacharyya, M. Koneru, J. English, F. Settecase, Warren T. Kim, P. Patel, Ajith Thomas, T. Jovin, R. Hanel, V. Benalia, G. Cortez, A. Aghaebrahim, E. Sauvageau, M. Abdalkader, Thanh N. Nguyen, P. Klein, A. Dmytriw, Hamza Shaikh","doi":"10.1161/svin.123.000940","DOIUrl":"https://doi.org/10.1161/svin.123.000940","url":null,"abstract":"\u0000 \u0000 Preliminary in vitro and early clinical experience of the Tenzing 7 delivery catheter demonstrated high success rates of aspiration catheter intracranial delivery with minimal complications. This study aimed to examine the efficacy, safety, and efficiency of the Tenzing 7 delivery catheter to deliver therapeutic devices in aspiration mechanical thrombectomy for acute ischemic strokes using clinical experience from multiple institutions.\u0000 \u0000 \u0000 \u0000 We performed a retrospective analysis of prospectively collected data from patients with acute ischemic stroke treated with aspiration mechanical thrombectomy using the Tenzing 7 delivery catheter between January 2020 and July 2022 at 6 high volume stroke centers. Primary efficacy outcome was success in aspiration catheter delivery to the face of the thrombus, and primary safety end point was rate of procedural complication.\u0000 \u0000 \u0000 \u0000 Of a total of 176 patients (mean age 70.1±14.9 years, 56.3% female, 89.2% middle cerebral artery occlusions), first‐pass effect (modified Thrombolysis in Cerebral Infarction score≥2B) was achieved in 90/166 (54.2%) successfully revascularized patients. Tenzing 7 delivered the aspiration catheter of choice to the site of occlusion in 95.9% of cases; the clot was not crossed with Tenzing 7 in 69% of cases. Successful recanalization (modified Thrombolysis in Cerebral Infarction score≥2B) was achieved in 94.9% of cases requiring a median of 1 pass (interquartile range 1–3). Nonflow limiting vessel dissection unrelated to Tenzing 7 occurred in 4 patients (2.3%), and intracranial vessel perforation unrelated to Tenzing 7 occurred in 4 cases (2.3%).\u0000 \u0000 \u0000 \u0000 This multicenter clinical experience using Tenzing 7 in mechanical thrombectomy demonstrated high rates of technical success and a modest complication rate, similar to the published rates of technical success with other thrombectomy techniques. The Tenzing 7 delivery catheter is effective and safe for the delivery of the aspiration catheter in patients undergoing thrombectomy for acute ischemic stroke.\u0000","PeriodicalId":74875,"journal":{"name":"Stroke (Hoboken, N.J.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44856313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号